617 results
Arrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. The company is leveraging its proprietary drug delivery technologies to develop targeted drugs based on the RNA interference mechanism that efficiently silence disease-causing genes. Arrowhead technologies also enable partners to create peptide-drug conjugates that specifically home to cell types of interest while sparing off-target tissues. Arrowhead’s pipeline includes clinical programs in chronic hepatitis B virus and obesity and partner-based programs in oncology.
At Arsia, we envision a world where medicines are delivered to patients easily, painlessly, and effectively.
Flemington, NJ
Artcraft Health Clinical Trials is dedicated to accelerating trial objectives through innovative health education solutions for investigators, healthcare professionals, site staff, participants, and caregivers.
ARUP Laboratories is a national clinical and anatomic pathology reference laboratory and a worldwide leader in innovative laboratory research and development. A nonprofit enterprise of the University of Utah, ARUP offers an extensive test menu of highly complex and unique medical tests.
New Haven, CT
Arvinas is a pharmaceutical company focused on developing new small molecule strategies aimed at degrading disease-causing cellular proteins. We are translating these innovative protein degradation approaches into novel drugs for the treatment of cancer and other diseases.
Newburyport, MA
Asentral, Inc. IRB is a company answering the rapidly increasing demand for ethical review and oversight of clinical research in the community setting.
ASLAN inlicenses preclinical candidate drugs and takes them to proof-of-concept, leveraging high quality resources in Asia, then offers them back to the originator or other pharma companies for late phase global development.
New York, NY
Assembly Biosciences is a biopharmaceutical company developing innovative treatments for hepatitis B virus infection (HBV) and C. difficile-associated diarrhea (CDAD). Both programs have breakthrough potential to provide higher cure rates for these debilitating diseases.
Biopharmaceutical
Biopharmaceutical

Pages